(4-iodo-2-thieno[2,3-c]pyridin-3-ylfuro[2,3-c]pyridin-7-yl)bis-carbamic acid tert-butyl ester | 1326713-95-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: (4-iodo-2-thieno[2,3-c]pyridin-3-ylfuro[2,3-c]pyridin-7-yl)bis-carbamic acid tert-butyl ester
• CAS: 1326713-95-4
• 化学式: C₂₄H₂₄IN₃O₅S
• 分子量: 593.442
• InChiKey: YNJHBCMDRSAPES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.39
• 重原子数：
  34.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  94.76
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (4-iodo-2-thieno[2,3-c]pyridin-3-ylfuro[2,3-c]pyridin-7-yl)bis-carbamic acid tert-butyl ester 、 六甲基二锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 生成 C₂₇H₃₃N₃O₅SSn
  参考文献：
  名称：

  Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics

  摘要：

  The kinase selectivity and pharmacokinetic optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. The intersection of insights from molecular modeling, computational prediction of metabolic sites, and in vitro metabolite identification studies resulted in a simple and unique solution to both of these problems. These efforts culminated in the discovery of compound 13a, a potent, relatively selective inhibitor of TAK1 with good pharmacokinetic properties in mice, which was active in an in vivo model of ovarian cancer. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.054
• 作为产物：
  描述：

  2-chlorofuro[2,3-c]pyridin-7-amine 在 4-二甲氨基吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-碘代丁二酰亚胺 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 (4-iodo-2-thieno[2,3-c]pyridin-3-ylfuro[2,3-c]pyridin-7-yl)bis-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics

  摘要：

  The kinase selectivity and pharmacokinetic optimization of a series of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1 is described. The intersection of insights from molecular modeling, computational prediction of metabolic sites, and in vitro metabolite identification studies resulted in a simple and unique solution to both of these problems. These efforts culminated in the discovery of compound 13a, a potent, relatively selective inhibitor of TAK1 with good pharmacokinetic properties in mice, which was active in an in vivo model of ovarian cancer. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.054

文献信息

• [EN] 7-AMINOFUROPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA 7-AMINOFUROPYRIDINE
  申请人：OSI PHARMACEUTICALS LLC

  公开号：WO2011100502A8

  公开（公告）日：2011-09-22